CENP-E-IN-1
CENP-E-IN-1 is a CENP-E inhibitor. CENP-E-IN-1 acts as a Mitotic arrest inducer and Apoptosis inducer, which causes abnormal alignment of chromosomes on the metaphase plate, activates the spindle assembly checkpoint and triggers apoptosis. CENP-E-IN-1 exhibits anti-tumor activity in colorectal adenocarcinoma xenograft models. CENP-E-IN-1 can be used in cancer-related research.
For research use only. We do not sell to patients.
- CAS No.: 1446399-26-3
- Formula: C30H27F4N5O4S
- Molecular Weight:629.63
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Kinesin Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
CENP-E |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | GI50 |
80 nM
|
Antiproliferative activity against asynchronous human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by ATP-based cell viability assay.
Antiproliferative activity against asynchronous human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by ATP-based cell viability assay.
|
26649895 |
In Vitro
CENP-E-IN-1 (Compound Cmpd-A) (200 nM; 3 h up to 12 h) induces pole-proximal chromosome misalignment, activates the SAC, and causes prolonged mitotic arrest in synchronized HeLa cells[1].
CENP-E-IN-1 (0-1000 nM; 24-72 h) potently inhibits proliferation in asynchronous HeLa cells with a GI50 of 80 nM, and its antiproliferative and pro-apoptotic effects are dependent on SAC activation via BubR1[1].
CENP-E-IN-1 (3-3000 nM; 3 days) exhibits potent antiproliferative activity across a broad range of human cancer cell lines, though sensitivity is not correlated with CENP-E mRNA expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Synchronized HeLa cells
-
Concentration:200 nM
-
Incubation Time:3 h; up to 12 h post-thymidine block release
-
Result:Caused pole-proximal chromosome misalignment in 77% of mitotic HeLa cells, compared to no misalignment in control cells.
Prevented progression to anaphase/telophase.
Reduced inter-kinetochore distances in misaligned chromosomes to 0.8 μm compared to aligned chromosomes in control or Cmpd-A-treated cells.
Arrested cells in the G2/M phase, with accumulation of pHH3-positive mitotic cells reaching 38.7% at 12 h post-release.
Induced elevated BubR1 phosphorylation and cyclin B1 accumulation, indicating spindle assembly checkpoint (SAC) activation.
-
Cell Line:Asynchronous HeLa cells
-
Concentration:0-1000 nM
-
Incubation Time:72 h (cell viability); 24 h (pHH3, caspase-3/7, siRNA experiments)
-
Result:Potently suppressed HeLa cell proliferation with a GI50 of 80 nM, and this activity correlated with increased pHH3-positive cells.
Induced dose-dependent caspase-3/7 activation and antiproliferation in non-silencing siRNA-transfected cells.
Drastically reduced both caspase-3/7 activation and antiproliferative effects in BubR1 siRNA-transfected cells, indicating dependence on SAC activation.
-
Cell Line:Multiple human cancer cell lines (DU145, COLO205, NIH-OVCAR3, RKO, ES2, SK-OV3, PC-3, SW620, CAPAN-2)
-
Concentration:3-3000 nM
-
Incubation Time:3 days
-
Result:Exhibited potent antiproliferative effects in multiple cancer cell lines including DU145, COLO205, NIH-OVCAR3, RKO, ES2, SK-OV3, and PC-3.
Showed resistance in some cell lines (SW620, CAPAN-2), with responses similar to MRC5 cells.
Demonstrated antiproliferative activity that did not significantly correlate with CENP-E mRNA expression levels in tested cancer cell lines (R2 = 0.0001).
Parmacokinetics
| Species | Dose | Route | Plasma Concentration |
|---|---|---|---|
| Mice[1] | 100 mg/kg | i.p. | 33.7 μg/mL |
In Vivo
CENP-E-IN-1 (100 mg/kg; i.p.; three doses at 0, 8, and 24 hours on day 1) produces potent antitumor activity, with a T/C % of 11% on Day 8, in COLO205 xenograft nude mice without significant body weight loss[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:nude mice (subcutaneous xenograft of COLO205 human colorectal cancer cells)[1]
-
Dosage:100 mg/kg
-
Administration:i.p.; three doses at 0, 8, and 24 hours on day 1
-
Result:Reduced mean tumor volume to approximately 400 mm3 on Day 8 post-administration, compared to over 800 mm3 in vehicle-treated mice.
Achieved a T/C % of 11% on Day 8.
Caused no significant body weight loss relative to vehicle controls.
Chemical Information
-
CAS No. 1446399-26-3
-
Molecular Weight 629.63
-
Formula C30H27F4N5O4S
-
SMILES
O=C(N(CCN(C)C)C(C1)C2=CC=C(C(C#N)=C2S1(=O)=O)C(F)(F)F)C3=C(N4C(OC)=CC=CC4=N3)C5=CC=C(C(C)=C5)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)